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The Keap1-Nrf2 pathway is the major regulator of cytoprotective responses to oxidative and
electrophilic stress. Although cell signaling pathways triggered by the transcription factor Nrf2 prevent
cancer initiation and progression in normal and premalignant tissues, in fully malignant cells Nrf2
activity provides growth advantage by increasing cancer chemoresistance and enhancing tumor cell
growth. In this graphical review, we provide an overview of the Keap1-Nrf2 pathway and its
dysregulation in cancer cells. We also brieﬂy summarize the consequences of constitutive Nrf2
activation in cancer cells and how this can be exploited in cancer gene therapy.
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The Keap1-Nrf2 pathway is the major regulator of cytoprotec-
tive responses to endogenous and exogenous stresses caused by
reactive oxygen species (ROS) and electrophiles [1]. The key
signaling proteins within the pathway are the transcription factor
Nrf2 (nuclear factor erythroid 2-related factor 2) that binds
together with small Maf proteins to the antioxidant response
element (ARE) in the regulatory regions of target genes, and
Keap1 (Kelch ECH associating protein 1), a repressor protein that
binds to Nrf2 and promotes its degradation by the ubiquitin
proteasome pathway (Fig. 1). Keap1 is a very cysteine-rich
protein, mouse Keap1 having a total of 25 and human 27 cysteine
residues, most of which can be modiﬁed in vitro by different
oxidants and electrophiles [2]. Three of these residues, C151, C273er B.V.
x: þ358 17 163 751.
evonen).
Open access under CC BY-NC-Nand C288, have been shown to play a functional role by altering
the conformation of Keap1 leading to nuclear translocation of
Nrf2 and subsequent target gene expression [3] (Fig. 1). The exact
mechanism whereby cysteine modiﬁcations in Keap1 lead to Nrf2
activation is not known, but the two prevailing but not mutually
exclusive models are (1) the ‘‘hinge and latch’’ model, in which
Keap1 modiﬁcations in thiol residues residing in the IVR of Keap1
disrupt the interaction with Nrf2 causing a misalignment of the
lysine residues within Nrf2 that can no longer be polyubiquiti-
nylated and (2) the model in which thiol modiﬁcation causes
dissociation of Cul3 from Keap1 [3]. In both models, the inducer-
modiﬁed and Nrf2-bound Keap1 is inactivated and, consequently,
newly synthesized Nrf2 proteins bypass Keap1 and translocate
into the nucleus, bind to the ARE and drive the expression of Nrf2
target genes such as NAD(P)H quinone oxidoreductase 1 (NQO1),
heme oxygenase 1 (HMOX1), glutamate-cysteine ligase (GCL)
and glutathione S transferases (GSTs) (Fig. 2). In addition to
modiﬁcations of Keap1 thiols resulting in Nrf2 target gene
induction, proteins such as p21 and p62 can bind to Nrf2 or
Keap1 thereby disrupting the interaction between Nrf2 and Keap1
[1,3] (Fig. 3).D license. 
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tant for cancer chemoprevention in normal and premalignant
tissues, in fully malignant cells Nrf2 activity provides growth
advantage by increasing cancer chemoresistance and enhancing
tumor cell growth [4]. Several mechanisms by which Nrf2
signaling pathway is constitutively activated in various cancers
have been described: (1) somatic mutations in Keap1 or the
Keap1 binding domain of Nrf2 disrupting their interaction; (2)
epigenetic silencing of Keap1 expression leading to defective
repression of Nrf2; (3) accumulation of disruptor proteins such
as p62 leading to dissociation of the Keap1-Nrf2 complex;
(4) transcriptional induction of Nrf2 by oncogenic K-Ras, B-Raf
and c-Myc; and (5) post-translational modiﬁcation of Keap1
cysteines by succinylation that occurs in familial papillary renal
carcinoma due to the loss of fumarate hydratase enzyme activity
[3–10] (Fig. 3). Constitutively abundant Nrf2 protein causes
increased expression of genes involved in drug metabolism
thereby increasing the resistance to chemotherapeutic drugs
and radiotherapy. In addition, high Nrf2 protein level is asso-
ciated with poor prognosis in cancer [4]. Overactive Nrf2 alsoN-term BTB IVR
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Fig. 1. Structures of Nrf2 and Keap1 and the cysteine code. (A) Nrf2 consists of 589
contains a bZip motif, a basic region – leucine zipper (L-Zip) structure, where the basic r
small Maf proteins. Neh6 functions as a degron to mediate degradation of Nrf2 in the
motifs, which are required for the interaction with Keap1, and a hydrophilic regi
polyubiquitination and degradation of Nrf2. (B) Keap1 consists of 624 amino acid res
domain and the Kelch domain, are separated by the intervening region (IVR). The BTB do
of Keap1 and binding with Cullin3 (Cul3). The Kelch domain and the C-terminal region
through its Neh2 ETGE and DLG motifs. Both ETGE and DLG bind to similar sites on the b
27 cysteines in human protein. Some of these cysteines are located near basic residues
pattern of the cysteine residues by electrophiles is known as the cysteine code. The cy
affect different Keap1 cysteines. The cysteine modiﬁcations lead to conformational chan
domains, thus inhibiting the polyubiquitination of Nrf2. The functional importance of C
suppression of Nrf2 and Cys151 for activation of Nrf2 by inducers [1,3].affects cell proliferation by directing glucose and glutamine
towards anabolic pathways augmenting purine synthesis and
inﬂuencing the pentose phosphate pathway to promote cell
proliferation [11] (Fig. 4).
Given that high Nrf2 activity commonly occurs in cancer cells
with adverse outcomes, there is a need for therapies to inhibit Nrf2.
Unfortunately, due to structural similarity with some other bZip
family members, the development of speciﬁc Nrf2 inhibitors is a
challenging task and only a few studies of Nrf2 inhibition have been
published to date. By screening natural products, Ren et al. [12]
identiﬁed an antineoplastic compound brusatol as an Nrf2 inhibitor
that enhances the chemotherapeutic efﬁcacy of cisplatin. In addition,
PI3K inhibitors [11,13] and Nrf2 siRNA [14] have been used to
inhibit Nrf2 in cancer cells. Recently, we have utilized an alternative
approach, known as cancer suicide gene therapy, to target cancer
cells with high Nrf2 levels. Nrf2-driven lentiviral vectors [15]
containing thymidine kinase (TK) are transferred into cancer cells
with high ARE activity and the cells are treated with a pro-drug,
ganciclovir (GCV). GCV is metabolized to GCV-monophosphate,
which is further phosphorylated by cellular kinases into a toxicKelch repeats C-term
297 613368
288   489    513
 288
                                        368                                           489
288  297 319 613
288  297                                                                    613
1 Neh3
                            589 Maf
ing
inding
L-Zip
BTB
Kelch
BTB
Kelch
Nrf2-Keap1 complex
g
C-term
624
288 319 395 406 434 489 513 518 583 622 624
amino acids and has six evolutionarily highly conserved domains, Neh1-6. Neh1
egion is responsible for DNA recognition and the L-Zip mediates dimerization with
nucleus. Neh4 and 5 are transactivation domains. Neh2 contains ETGE and DLG
on of lysine residues (7 K), which are indispensable for the Keap1-dependent
idues and has ﬁve domains. The two protein–protein interaction motifs, the BTB
main together with the N-terminal portion of the IVR mediates homodimerization
mediate the interaction with Neh2. (C) Nrf2 interacts with two molecules of Keap1
ottom surface of the Keap1 Kelch motif. (D) Keap1 is rich in cysteine residues, with
and are therefore excellent targets of electrophiles and oxidants. The modiﬁcation
steine code hypothesis proposes that structurally different Nrf2 activating agents
ges in the Keap1 disrupting the interaction between the Nrf2 DLG and Keap1 Kelch
ys151, Cys273 and Cys288 has been shown, as Cys273 and Cys288 are required for
Fig. 2. The Nrf2-Keap1 signaling pathway. (A and B) in basal conditions, two Keap1 molecules bind to Nrf2 and Nrf2 is polyubiquitylated by the Cul3-based E3
ligase complex. This polyubiquitilation results in rapid Nrf2 degradation by the proteasome. A small proportion of Nrf2 escapes the inhibitory complex and
accumulates in the nucleus to mediate basal ARE-dependent gene expression, thereby maintaining the cellular homeostasis. (C) Under stress conditions, inducers
modify the Keap1 cysteines leading to the inhibition of Nrf2 ubiquitylation via dissociation of the inhibitory complex. (D) According to the hinge and latch model,
modiﬁcation of speciﬁc Keap1 cysteine residues leads to conformational changes in Keap1 resulting in the detachment of the Nrf2 DLG motif from Keap1.
Ubiquitination of Nrf2 is disrupted but the binding with the ETGE motif remains. (E) In the Keap1-Cul3 dissociation model, the binding of Keap1 and Cul3 is
disrupted in response to electrophiles, leading to the escape of Nrf2 from the ubiquitination system. In both of the suggested models, the inducer-modiﬁed and
Nrf2-bound Keap1 is inactivated and, consequently, newly synthesized Nrf2 proteins bypass Keap1 and translocate into the nucleus, bind to the Antioxidant
Response Element (ARE) and drive the expression of Nrf2 target genes such as NQO1, HMOX1, GCL and GSTs [1,3].
Fig. 3. Mechanisms for constitutive nuclear accumulation of Nrf2 in cancer. (A) Somatic mutations in Nrf2 or Keap1 disrupt the interaction of these two proteins. In Nrf2,
mutations affect ETGE and DLG motifs, but in Keap1 mutations are more evenly distributed. Furthermore, oncogene activation, such as KrasG12D [5], or disruption of tumor
suppressors, such as PTEN [11] can lead to transcriptional induction of Nrf2 and an increase in nuclear Nrf2. (B) Hypermethylation of the Keap1 promoter in lung and
prostate cancer leads to reduction of Keap1 mRNA expression, which increases the nuclear accumulation of Nrf2 [6,7]. (C) In familial papillary renal carcinoma, the loss of
fumarate hydratase enzyme activity leads to the accumulation of fumarate and further to succination of Keap1 cysteine residues (2SC). This post-translational modiﬁcation
leads to the disruption of Keap1-Nrf2 interaction and nuclear accumulation of Nrf2 [8,9]. (D) Accumulation of disruptor proteins such as p62 and p21 can disturb Nrf2-
Keap1 binding and results in an increase in nuclear Nrf2. p62 binds to Keap1 overlapping the binding pocket for Nrf2 and p21 directly interacts with the DLG and ETGE
motifs of Nrf2, thereby competing with Keap1 [10].
E. Kansanen et al. / Redox Biology 1 (2013) 45–49 47triphosphate form [16] (Fig. 5). This leads to effective killing of not
only TK containing tumor cells, but also the neighboring cells due to
the bystander effect [17]. ARE-regulated TK/GCV gene therapy canbe further enhanced via combining a cancer chemotherapeutic agent
doxorubicin to the treatment [16], supporting the notion that this
approach could be useful in conjuction with traditional therapies.
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Fig. 4. The dual role of Nrf2 in tumorigenesis. Under physiological conditions, low levels of nuclear Nrf2 are sufﬁcient for the maintenance of cellular homeostasis. Nrf2
inhibits tumor initiation and cancer metastasis by eliminating carcinogens, ROS and other DNA-damaging agents. During tumorigenesis, accumulating DNA damage leads
to constitutive hyperactivity of Nrf2 which helps the autonomous malignant cells to endure high levels of endogenous ROS and to avoid apoptosis. Persistently elevated
nuclear Nrf2 levels activate metabolic genes in addition to the cytoprotective genes contributing to metabolic reprogramming and enhanced cell proliferation. Cancers
with high Nrf2 levels are associated with poor prognosis because of radio and chemoresistance and aggressive cancer cell proliferation. Thus, Nrf2 pathway activity is
protective in the early stages of tumorigenesis, but detrimental in the later stages. Therefore, for the prevention of cancer, enhancing Nrf2 activity remains an important
approach whereas for the treatment of cancer, Nrf2 inhibition is desirable [4,11].
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Fig. 5. Suicide gene therapy. Constitutive Nrf2 nuclear accumulation in cancer cells can be exploited by using Nrf2-driven viral vector for cancer suicide gene
therapy [16]. In this approach, lentiviral vector (LV) expressing thymidine kinase (TK) under minimal SV40 promoter with four AREs is transduced to lung adenocarcinoma
cells. High nuclear Nrf2 levels lead to robust expression of TK through Nrf2 binding. Cells are then treated with a pro-drug, ganciclovir (GCV), which is phosphorylated by
TK. Triphosphorylated GCV disrupts DNA synthesis and leads to effective killing of not only TK containing tumor cells, but also the neighboring cells due to the bystander
effect.
E. Kansanen et al. / Redox Biology 1 (2013) 45–4948Acknowledgments
This work was supported by the Academy of Finland, the Sigrid
Juselius Foundation and the Finnish Cancer Organisations.References
[1] E. Kansanen, H.-K. Jyrkka¨nen, A.-L. Levonen, Activation of stress signaling
pathways by electrophilic oxidized and nitrated lipids, Free Radical Biology
and Medicine 52 (2012) 973–982.
E. Kansanen et al. / Redox Biology 1 (2013) 45–49 49[2] E. Kansanen, A.M. Kivela¨, A.-L. Levonen, Regulation of Nrf2-dependent gene
expression by 15-deoxy-Delta12,14-prostaglandin J2, Free Radical Biology
and Medicine 47 (2009) 1310–1317.
[3] K. Taguchi, H. Motohashi, M. Yamamoto, Molecular mechanisms of the
Keap1–Nrf2 pathway in stress response and cancer evolution, Genes Cells
16 (2011) 123–140.
[4] M.B. Sporn, K.T. Liby, NRF2 and cancer: the good, the bad and the importance
of context, Nature Reviews Cancer 12 (2012) 564–571.
[5] G.M. DeNicola, F.A. Karreth, T.J. Humpton, A. Gopinathan, C. Wei, K.
Frese, D. Mangal, K.H. Yu, C.J. Yeo, E.S. Calhoun, F. Scrimieri, J.M. Winter,
R.H. Hruban, C. Iacobuzio-Donahue, S.E. Kern, I.A. Blair, D.A. Tuveson,
Oncogene-induced Nrf2 transcription promotes ROS detoxiﬁcation and
tumorigenesis, Nature 475 (2011) 106–109.
[6] N. Hanada, T. Takahata, Q. Zhou, X. Ye, R. Sun, J. Itoh, A. Ishiguro, H. Kijima,
J. Mimura, K. Itoh, S. Fukuda, Y. Saijo, Methylation of the KEAP1 gene
promoter region in human colorectal cancer, BMC Cancer 12 (2012) 66.
[7] P. Zhang, A. Singh, S. Yegnasubramanian, D. Esopi, P. Kombairaju, M. Bodas,
H. Wu, S.G. Bova, S. Biswal, Loss of Kelch-like ECH-associated protein
1 function in prostate cancer cells causes chemoresistance and radioresis-
tance and promotes tumor growth, Molecular Cancer Therapeutics 9 (2010)
336–346.
[8] J. Adam, E. Hatipoglu, L. O’Flaherty, N. Ternette, N. Sahgal, H. Lockstone,
D. Baban, E. Nye, G.W. Stamp, K. Wolhuter, M. Stevens, R. Fischer,
P. Carmeliet, P.H. Maxwell, C.W. Pugh, N. Frizzell, T. Soga, B.M. Kessler,
M. El-Bahrawy, P.J. Ratcliffe, et al., Renal cyst formation in Fh1-deﬁcient mice
is independent of the Hif/Phd pathway: roles for fumarate in KEAP1
succination and Nrf2 signaling, Cancer Cell 20 (2011) 524–537.
[9] A. Ooi, J.-C. Wong, D. Petillo, D. Roossien, V. Perrier-Trudova, D. Whitten,
B.W.H. Min, M.-H. Tan, Z. Zhang, X.J. Yang, M. Zhou, B. Gardie, V. Molinie´,
S. Richard, P.H. Tan, B.T. Teh, K.A. Furge, An antioxidant response phenotype
shared between hereditary and sporadic type 2 papillary renal cell carci-
noma, Cancer Cell 20 (2011) 511–523.[10] Q. Ma, X. He, Molecular basis of electrophilic and oxidative defense: promises
and perils of nrf2, Pharmacological Reviews 64 (2012) 1055–1081.
[11] Y. Mitsuishi, K. Taguchi, Y. Kawatani, T. Shibata, T. Nukiwa, H. Aburatani,
M. Yamamoto, H. Motohashi, Nrf2 redirects glucose and glutamine into
anabolic pathways in metabolic reprogramming, Cancer Cell 22 (2012)
66–79.
[12] D. Ren, N.F. Villeneuve, T. Jiang, T. Wu, A. Lau, H.A. Toppin, D.D. Zhang,
Brusatol enhances the efﬁcacy of chemotherapy by inhibiting the Nrf2-
mediated defense mechanism, Proceedings of the National Academy of
Sciences USA 108 (2011) 1433–1438.
[13] S. Chowdhry, Y. Zhang, M. McMahon, C. Sutherland, A. Cuadrado, J.D. Hayes,
Nrf2 is controlled by two distinct b-TrCP recognition motifs in its Neh6
domain, one of which can be modulated by GSK-3 activity, Oncogene (2012).
[14] A. Singh, S. Boldin-Adamsky, R.K. Thimmulappa, S.K. Rath, H. Ashush,
J. Coulter, A. Blackford, S.N. Goodman, F. Bunz, W.H. Watson, E. Gabrielson,
E. Feinstein, S. Biswal, RNAi-mediated silencing of nuclear factor erythroid-2-
related factor 2 gene expression in non-small cell lung cancer inhibits tumor
growth and increases efﬁcacy of chemotherapy, Cancer Research 68 (2008)
7975–7984.
[15] H. Hurttila, J.K. Koponen, E. Kansanen, H.-K. Jyrkka¨nen, A. Kivela¨, R. Kyla¨tie,
S. Yla¨-Herttuala, A.-L. Levonen, Oxidative stress-inducible lentiviral vectors
for gene therapy, Gene Therapy 15 (2008) 1271–1279.
[16] H.M. Leinonen, A.-K. Ruotsalainen, A.-M. Ma¨a¨tta¨, H.M. Laitinen,
S.M. Kuosmanen, E. Kansanen, J.T. Pikkarainen, J.P. Lappalainen,
H. Samaranayake, H.P. Lesch, M.U. Kaikkonen, S. Yla¨-Herttuala, A.-
L. Levonen, Oxidative stress-regulated lentiviral TK/GCV gene therapy for
lung cancer treatment, Cancer Research 23 (2012) 6227–6235.
[17] F.L. Moolten, Tumor chemosensitivity conferred by inserted herpes thymi-
dine kinase genes: paradigm for a prospective cancer control strategy, Cancer
Research 46 (1986) 5276–5281.
